Trial purpose
Cancer treatment
Tumor type
Haematological
Age
16+
Clinical summary
Summary
This study will be conducted in 2 parts (Dose Escalation and Expansion) and will be evaluating a new drug, called GEN3017, in people with relapsed/refractory (R/R) CD30+ classical Hodgkin lymphoma (cHL) and R/R CD30+ T-cell lymphoma.
The Dose Escalation part of the study will evaluate how safe and tolerable GEN3017 is, and aims to determine the recommended phase 2 dose (RP2D) and, if reached, the maximum tolerated dose (MTD).
The Expansion Part will further evaluate the safety and effectiveness of GEN3017 at the RP2D identified in the Dose Escalation part, and at other selected doses.
Conditions
This trial is treating people with CD30+ classical Hodgkin lymphoma and T-cell lymphoma
Eligibility
Inclusion
Dose Escalation Part:
- Must be at least 18 years of age. For participants in the R/R cHL Cohort in the United States (US) and Australia, must be at least 16 years of age.
- Histologically confirmed R/R cHL or R/R TCL.
- Participants must have at least 1 measurable lesion by fluorodeoxyglucose-positron emission tomography (FDG-PET) scan demonstrating positive lesion compatible with computed tomography (CT)- or magnetic resonance imaging (MRI)-defined anatomical tumor sites and a CT scan (or MRI) with involvement of ≥1 measurable nodal lesion and/or ≥1 measurable extranodal lesion.
- Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1 for participants 18 years of age and above. For participants ≥16 and <18 years of age (US and Australia only), Karnofsky score of >60% per Karnofsky performance scale.
- Confirmed CD30-positivity in tumor biopsy prior to the first dose of GEN3017.
-
R/R cHL Cohort:
- Must have relapsed or progressive cHL after receiving at least 2 or 3 prior lines of therapy; OR
- Refractory to the second line of therapy.
Exclusion
- Primary central nervous system (CNS) tumor or known CNS involvement.
- Received prior investigational CD30-targeting therapy (except brentuximab vedotin).
- Autologous hematopoietic stem cell transplant (HSCT) within 60 days (applies to both cHL and TCL). Allogeneic HSCT within 90 days (applies to cHL) prior to the first dose of GEN3017.
- Chemotherapy within 2 weeks or major surgery within 4 weeks prior to the first dose of GEN3017.
- Curative radiotherapy within 4 weeks or palliative radiotherapy within 2 weeks prior to the first dose of GEN3017.
- Treatment with an investigational drug within 4 weeks or 5 half-lives of the drug, whichever is shorter prior to the first dose of GEN3017 or currently receiving any other investigational agents.
- Prior treatment with live, attenuated vaccines within 30 days prior to the first dose of GEN3017.
- Receiving immunosuppressive drugs or systemic corticosteroids such as prednisone at doses >25 milligrams (mg) daily or its equivalent within 14 days prior to the first dose of GEN3017.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Inclusion
- You have had treatment, but your cancer has come back (relapsed or recurrent).
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
Exclusion
- You have had certain treatments, surgical procedures or drugs.
- You are currently being treated on a clinical trial.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ClinicalTrials.gov *. View further details about this trial on the registry via the links below:
Trial sponsor
Genmab
Scientific Title
A Phase 1/2a, Open-Label, Dose Escalation Trial of GEN3017 With Expansion Cohorts in Relapsed or Refractory CD30+ Classical Hodgkin Lymphoma and CD30+ Non-Hodgkin Lymphoma
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Cancer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Cancer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.
Get support
Learn more about clinical trials through this collection of resources in languages other than English.
View information